XENON PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
XENON PHARMACEUTICALS INC. (XENE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-06-30 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-09-30 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-06-30 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- XENON PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-03 | 0.00% 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-06 | 0.00% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-03 | 0.00% 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-11 | 0.00% 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | 0.00% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-08 | 0.00% 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | 0.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-08 | 0.00% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-09 | 0.00% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2024-02-29 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-08 | 0.00% 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-09 | 0.00% 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 0.00% 10-K · filed 2023-03-01 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | 0.00% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.00% 10-Q · filed 2021-08-11 | 0.00% 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-01 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-05 | 0.00% 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 0.00% 10-Q/A · filed 2020-05-26 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-09 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-11-05 | 0.00% 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-08-06 | 0.00% 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-06 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-06 | 0.00% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-07 | 0.00% 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 0.00% 10-K · filed 2018-03-07 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-07 | 0.00% 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-03 | 0.00% 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-07 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-03 | 0.00% 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-03 | 0.00% 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-08 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-10 | 0.00% 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-13 | 0.00% 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | 0.00% 10-Q/A · filed 2015-08-13 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-08 | |||
| 2013-09-30 | 0.00% 10-Q · filed 2014-12-15 | 0.00% 10-Q · filed 2014-12-15 | ||
| 2012-12-31 | 0.00% 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |